Ljubljana, Slovenia

Alenka Kosak

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2009.


% Patents Active = 100.0


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alenka Kosak: Innovator in Pharmaceutical Chemistry

Introduction

Alenka Kosak is a prominent inventor based in Ljubljana, Slovenia. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel drug formulations. Her work has been recognized for its potential impact on the treatment of gastrointestinal disorders.

Latest Patents

Alenka Kosak holds a patent for a crystalline form of omeprazole. This novel crystalline form, known as omeprazole form C, is characterized by its chemical composition, specifically 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole. The patent also details a process for preparing omeprazole form C, a pharmaceutical formulation containing this form in combination with pharmaceutically acceptable excipients, and its use in treating gastrointestinal disorders. She has 1 patent to her name.

Career Highlights

Alenka Kosak is associated with Lek Pharmaceuticals D.d., a leading pharmaceutical company in Slovenia. Her role at the company has allowed her to focus on innovative drug development and contribute to advancements in pharmaceutical science.

Collaborations

Alenka has collaborated with notable colleagues, including Natasa H Milac and Anton Copar. These partnerships have fostered a collaborative environment that enhances research and development efforts within the company.

Conclusion

Alenka Kosak's contributions to pharmaceutical chemistry, particularly through her patent on omeprazole form C, highlight her innovative spirit and dedication to improving healthcare solutions. Her work continues to influence the field and offers promising avenues for future research and development.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…